Lotus Eye Hospital sets Sept 23 AGM for MD pay hike, director vote
- Lotus Eye Hospital schedules AGM on September 23, 2026, for MD pay hike
- MD Sangeetha Sundaramoorthy's monthly salary proposed to rise to ₹6 lakh
- FY26 revenue grew 8.4% to ₹5,371 lakh; PAT fell 89% to ₹8 lakh
- New borrowings of ₹1,142 lakh taken for expansion; assets up 18.7%
- Shareholders to reappoint Dr. Kavetha Sundaramoorthy by rotation

*this image is generated using AI for illustrative purposes only.
Lotus Eye Hospital has scheduled its 29th Annual General Meeting for September 23, 2026, to approve a significant increase in the Managing Director’s remuneration and the reappointment of a retiring director. The meeting will be conducted via video conferencing.
Shareholders will consider an ordinary resolution to raise Ms. Sangeetha Sundaramoorthy’s monthly salary from ₹3,50,000 to ₹6,00,000, effective August 10, 2026. This revision applies to her remaining tenure until August 14, 2028. The Board cited her contribution to growth and expansion plans as justification for the hike.
Governance Changes
The agenda also includes the reappointment of Dr. Kavetha Sundaramoorthy, who retires by rotation. Additionally, shareholders must pass a special resolution to continue paying Dr. Kuttapalayam Songappan Ramalingam a monthly remuneration of ₹1,00,000 for FY27. This approval is required under SEBI LODR regulations because his annual pay exceeds 50% of the total remuneration for all non-executive directors.
Financial Context
The company reported a turnover of ₹5,489.03 lakh and a profit after tax of ₹8.04 lakh for FY26. Revenue from operations grew 8.4% year-on-year to ₹5,371.41 lakh from ₹4,956.25 lakh in FY25. However, net profit declined sharply from ₹73.93 lakh in the previous year due to initial costs associated with new center investments, including a facility in Gobichettipalayam. Management expects these investments to improve margins in the long run.
| Metric | FY26 | FY25 | Change |
|---|---|---|---|
| Revenue from Operations | ₹5,371.41 lakh | ₹4,956.25 lakh | +8.4% |
| Profit After Tax | ₹8.04 lakh | ₹73.93 lakh | -89.1% |
| Total Assets | ₹8,259.74 lakh | ₹6,957.37 lakh | +18.7% |
What the Numbers Show
The proposed remuneration revision represents a 71% increase in the Managing Director’s monthly fixed emoluments. With the company reporting a PAT of just ₹8.04 lakh against a turnover of ₹5,489.03 lakh in FY26, the annualized cost of this hike (₹30 lakh per year) is substantial relative to current profitability levels. Furthermore, the company’s total borrowings increased significantly to ₹1,142.97 lakh from nil in the prior year, reflecting debt-funded expansion.
Voting Details
Remote e-voting will be available from September 20 to September 22, 2026. The record date for determining voting eligibility is September 16, 2026. Shareholders holding shares as on this date may cast votes electronically through CDSL.
Historical Stock Returns for Lotus Eye Hospital
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.06% | -5.51% | -7.12% | -0.95% | -6.59% | +150.03% |
How will the 71% increase in the Managing Director's remuneration impact shareholder returns given the sharp 89% decline in PAT and current debt levels?
What specific performance metrics or revenue targets must the new Gobichettipalayam facility achieve to justify the initial investment costs that suppressed FY26 profits?
Will the significant rise in total borrowings to ₹1,142.97 lakh affect the company's interest coverage ratio and long-term financial stability during the expansion phase?


































